BioSpace News Archive

Croma-Pharma announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom, and Ireland.

Covis Finco Sarl, announced the closing of its financial recapitalization transaction per the previously announced Support Agreement entered into with its Equity Sponsors, 100% of its First Lien Lenders and 100% of its Second Lien Lenders.

Medigene AG announces its pipeline expansion into neoantigens with KRAS as the first target in its MDG10xx program, a T cell receptor engineered T cell therapy being developed in combination with the company’s PD1-41BB switch receptor technology.

Mallinckrodt plc today announced the presentation of results from two clinical studies in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 treated with TERLIVAZ® (terlipressin) for injection at the American Transplant Congress (ATC) 2023, taking place in San Diego, Calif. from June 3-7, 2023.

BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:30 p.m. ET in New York.

Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).

Monopar Therapeutics Inc. today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS).

atai Life Sciences will participate in upcoming June Investor Conferences. Details of the company’s participation are as follows.

Seegene Inc. announced today that it has obtained the European Union’s In Vitro Diagnostic Medical Device Regulation (IVDR) certification for 30 diagnostic assays.